Yayın:
The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment

Basit Görünüm
dc.contributor.authorMarcellin, Patrick
dc.contributor.authorBonino, Ferruccio
dc.contributor.authorLau, George
dc.contributor.authorFarci, Patrizia
dc.contributor.authorYurdaydin, C.
dc.contributor.authorPiratvisuth, Teerha
dc.contributor.authorJin, R.
dc.contributor.authorHadziyannis, Stephanos J.
dc.contributor.authorLu, Zhimeng
dc.contributor.authorPopescu, Madalina
dc.contributor.buuauthorGürel, Selim
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.departmentGastroenteroloji Bilim Dalı
dc.date.accessioned2022-11-01T06:35:41Z
dc.date.available2022-11-01T06:35:41Z
dc.date.issued2006
dc.descriptionBu çalışma, 26-30 Nisan 2006 tarihleri arasında Vienna[Avusturya]’da düzenlenen 41. Annual Meeting of the European-Association-for-the-Study-of-the-Liver’da bildiri olarak sunulmuştur.
dc.description.sponsorshipEuropean Assoc Study Liver
dc.identifier.citationMarcellin, P. vd. (2006). ''The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment''. Journal of hepatology, 44(Suplement 2), S275-S275.
dc.identifier.doi10.1016/S0168-8278(06)80744-0
dc.identifier.endpageS275
dc.identifier.issn0168-8278
dc.identifier.issueSupplement 2
dc.identifier.startpageS275
dc.identifier.urihttps://doi.org/10.1016/S0168-8278(06)80744-0
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0168827806807440
dc.identifier.urihttp://hdl.handle.net/11452/29287
dc.identifier.volume44
dc.identifier.wos000237328100744
dc.indexed.wosSCIE
dc.indexed.wosCPCIS
dc.language.isoen
dc.publisherElsevier
dc.relation.collaborationYurt dışı
dc.relation.collaborationYurt içi
dc.relation.journalJournal of hepatology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGastroenterology & hepatology
dc.subject.wosGastroenterology & hepatology
dc.titleThe majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment
dc.typeOther
dc.type.subtypeMeeting Abstract
dc.wos.quartileQ1
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı/Gastroenteroloji Bilim Dalı
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama
İndir

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications